<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715143</url>
  </required_header>
  <id_info>
    <org_study_id>CR05-005</org_study_id>
    <nct_id>NCT00715143</nct_id>
  </id_info>
  <brief_title>Post Approval Study: NOVATION Ceramic Articulation Hip System</brief_title>
  <official_title>Post Approval Study: NOVATION Ceramic Articulation Hip System A Multi-Center, Open-Label Study to Evaluate the Mid and Long-Term Safety and Effectiveness of the Exactech NOVATION Ceramic Articulation Hip System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exactech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exactech</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect and evaluate long-term safety and effectiveness data&#xD;
      on the Exactech® NOVATION ™ Ceramic Articulation Hip System (&quot;NOVATION ™ Ceramic AHS&quot;). Ten&#xD;
      (10) years of follow-up data will be collected in this study. The first five (5) years of&#xD;
      subject follow-up will involve clinical (Harris Hip Score, adverse events), radiographic, and&#xD;
      self-assessment evaluation. The remaining five (5) years of subject follow-up will be&#xD;
      accomplished with an outcomes questionnaire that will be completed by the subjects to&#xD;
      evaluate the survivorship status of their hip replacement.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic evaluation of radiolucency</measure>
    <time_frame>Immediately post operation, 6 weeks, 6 months, annually 1-5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Survivorship of device components</measure>
    <time_frame>Immediately post operation, 6 weeks, 6 months, annually 1-5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Harris Hip Score</measure>
    <time_frame>Immediately post operation, 6 weeks, 6 months, annually 1-5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Total Hip Replacement (Non-inflammatory)</condition>
  <arm_group>
    <arm_group_label>N</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This treatment arm includes ceramic-on-ceramic hip device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Novation Ceramic</intervention_name>
    <description>This treatment is the study device (which will be compared to a similar historic control device)</description>
    <arm_group_label>N</arm_group_label>
    <other_name>Novation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Patient is undergoing primary hip surgery for symptomatic Non-inflammatory&#xD;
             Degenerative Joint Disease (NIDJD). Composite diagnosis of NIDJD includes osteo/&#xD;
             degenerative arthritis, traumatic arthritis, congenital hip dysplasia and avascular&#xD;
             necrosis.&#xD;
&#xD;
          2. Patient is 21 years of age or older at the time of surgery.&#xD;
&#xD;
          3. Patient is skeletally mature (tibial and femoral epiphyses are closed).&#xD;
&#xD;
          4. Patient is willing and able to return for follow-up as specified by the study protocol&#xD;
             over a ten (10) year post-operative follow-up period; including 5 years of in-clinic&#xD;
             visits followed by 5 years of mail-in questionnaire follow-up.&#xD;
&#xD;
          5. Patient is female and of childbearing age, for whom a negative urine pregnancy test is&#xD;
             obtained immediately prior to surgery.&#xD;
&#xD;
          6. Patient does not meet any of the Exclusion Criteria.&#xD;
&#xD;
          7. Patient agrees to participate and sign the Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Patient will be less than 21 years old at the time of surgery.&#xD;
&#xD;
          2. Patient is skeletally immature.&#xD;
&#xD;
          3. Patient presents with inflammatory degenerative joint disease.&#xD;
&#xD;
          4. Patient has evidence of active infection, but not including asymptomatic urinary tract&#xD;
             infection (UTI) if treated with antibiotics preoperatively.&#xD;
&#xD;
          5. Patient is female and of child bearing age and is pregnant or whose pregnancy status&#xD;
             is unknown.&#xD;
&#xD;
          6. Patient has neurological or musculoskeletal disease that may adversely affect gait or&#xD;
             weight bearing.&#xD;
&#xD;
          7. Patient has known presence of active metastatic or neoplastic disease (active is&#xD;
             defined as within the past 5 years. Does not include basal cell carcinoma in cases&#xD;
             when a subject with this diagnosis has undergone radical excision of the lesion, has&#xD;
             pathological proof that the lesion has clean and clear peripheral and deep borders,&#xD;
             and the location of the lesion is not near the operative hip or on the affected&#xD;
             extremity).&#xD;
&#xD;
          8. Patient has poor bone quality (e.g., osteoporosis) where, in the investigator's&#xD;
             opinion, there is inadequate bone to support the implant(s).&#xD;
&#xD;
          9. Patient has the presence of a previous prosthetic hip replacement device (any type,&#xD;
             including THA, surface replacement arthroplasty, endoprosthesis, etc.) in the&#xD;
             operative hip joint.&#xD;
&#xD;
         10. Patient is known to have presence of a highly communicable disease or diseases that&#xD;
             may limit follow-up (e.g., immuno-compromised conditions, hepatitis, active&#xD;
             tuberculosis, etc.).&#xD;
&#xD;
         11. Patient is a prisoner.&#xD;
&#xD;
         12. Patient is obese where obesity is defined as a Body Mass Index (BMI) greater than 35.&#xD;
             BMI = Weight (lbs.) ÷ Height (in.)2 x 703&#xD;
&#xD;
         13. Patient has neuropathic joints.&#xD;
&#xD;
         14. Patient has known allergies to the implant materials.&#xD;
&#xD;
         15. Patient is unwilling or unable to comply with postoperative rehabilitation&#xD;
             instructions and weight bearing limitations.&#xD;
&#xD;
         16. Patient's life expectancy is &lt; 5 years due to chronic diseases such as cancer,&#xD;
             congestive heart failure, etc.&#xD;
&#xD;
         17. Patient is unwilling or unable (e.g. cases of reduced mental capacity) to return for&#xD;
             follow-up as specified by the study protocol over a ten (10) year post-operative&#xD;
             follow-up period.&#xD;
&#xD;
         18. Patient has reduced mental capability (permanent or temporary) that would prevent&#xD;
             following pre-surgical and post-surgical instructions.&#xD;
&#xD;
         19. Patient otherwise meets the study criteria but refuses to consent in writing to&#xD;
             participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rena White</last_name>
    <role>Study Director</role>
    <affiliation>Exactech</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rena White</last_name>
    <phone>352-377-1140</phone>
    <email>rena.white@exac.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shrock Orthopedic Research</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Schwartz</last_name>
      <phone>954-626-3743</phone>
      <email>Wendy@shrockresearch.com</email>
    </contact>
    <investigator>
      <last_name>Kevin Shrock, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Resurgens Orthopaedics</name>
      <address>
        <city>Cumming</city>
        <state>Georgia</state>
        <zip>30041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Jo Satusky, RN</last_name>
      <phone>678-341-6789</phone>
      <email>satuskymj@resurgens.com</email>
    </contact>
    <investigator>
      <last_name>David Covall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fallon Clinic</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Preusse, RN</last_name>
      <phone>508-595-2219</phone>
      <email>Peggy.Preusse@reliantmedicalgroup.org</email>
    </contact>
    <investigator>
      <last_name>William Balcom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulsa Bone &amp; Joint Associates</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracee Thomas</last_name>
      <phone>918-392-1400</phone>
      <email>tracthomas@cox.net</email>
    </contact>
    <investigator>
      <last_name>Scott Dunitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hampton Roads Orthopaedics &amp; Sports Medicine</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Carter, RN</last_name>
      <phone>757-873-1554</phone>
      <email>mcarter@hrosm.com</email>
    </contact>
    <investigator>
      <last_name>John Aldridge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>July 11, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2008</study_first_posted>
  <last_update_submitted>February 9, 2015</last_update_submitted>
  <last_update_submitted_qc>February 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hip</keyword>
  <keyword>replacement</keyword>
  <keyword>ceramic</keyword>
  <keyword>orthopaedic</keyword>
  <keyword>joint</keyword>
  <keyword>degenerative</keyword>
  <keyword>non-inflammatory</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>avascular necrosis</keyword>
  <keyword>congenital hip dysplasia</keyword>
  <keyword>traumatic arthritis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

